# A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

> **NCT04516278** · PHASE3 · COMPLETED · sponsor: **Outlook Therapeutics, Inc.** · enrollment: 195 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration
- BRVO - Branch Retinal Vein Occlusion
- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT04516278
- **Lead sponsor:** Outlook Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-02-10
- **Final completion:** 2021-02-10
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516278, "A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04516278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*